Positive PD‑L1 expression is predictive for patients with advanced EGFR wild‑type non‑small cell lung cancer treated with gemcitabine and cisplatin
Yajuan Qiu(Lymphoma Research Foundation), Yanru Qin(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Junguang Jiang(First Affiliated Hospital of Zhengzhou University)
Cited by 4
Related Papers
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF
|Oncogene|2017|141
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140